Literature DB >> 19426419

Intensity of continuous renal replacement therapy in acute kidney injury.

Paul M Palevsky1.   

Abstract

The intensity of continuous renal replacement therapy (CRRT) is generally assessed on the basis of small solute clearance with dosing usually expressed in terms of total effluent volume per unit time (e.g., ml/kg/hour). Although several clinical trials have suggested an improvement in survival with higher doses of CRRT, results have not been consistent across all studies. The results of recent trials of intensity of CRRT are reviewed. The largest and most recent trials suggest that there is no additional benefit to using effluent flow rates in excess of 20 ml/kg/hour, although earlier studies suggested improved survival with doses of 35 to 45 ml/kg/hour.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19426419     DOI: 10.1111/j.1525-139X.2008.00543.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  5 in total

1.  Solute clearance in CRRT: prescribed dose versus actual delivered dose.

Authors:  William D Lyndon; Keith M Wille; Ashita J Tolwani
Journal:  Nephrol Dial Transplant       Date:  2011-09-05       Impact factor: 5.992

2.  [Treatment of acute renal failure in Germany: Analysis of current practice].

Authors:  M Schmitz; P J Heering; R Hutagalung; R Schindler; M I Quintel; F M Brunkhorst; S John; A Jörres
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-03-28       Impact factor: 0.840

Review 3.  Dosing of renal replacement therapy in acute kidney injury.

Authors:  Anitha Vijayan; Paul M Palevsky
Journal:  Am J Kidney Dis       Date:  2012-01-11       Impact factor: 8.860

4.  Variability in Uremic Control during Continuous Venovenous Hemodiafiltration in Trauma Patients.

Authors:  Sigrid Beitland; Kjetil Sunde; Harald Moen; Ingrid Os
Journal:  Crit Care Res Pract       Date:  2012-05-17

Review 5.  Does Your Program Know Its AKI and CRRT Epidemiology? The Case for a Dashboard.

Authors:  Theresa A Mottes
Journal:  Front Pediatr       Date:  2020-03-06       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.